Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SB1518 in advanced myeloid malignancies
NCT00719836Phase 2Completed
- Sponsor
- S*BIO
- Start
- Aug 2008
- Primary completion
- Jan 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of pacritinib in myelofibrosis (MF), acute myeloid leukemia (AML), chronic myeloid leukemia (CML), chronic myelomonocytic leukemia (CMML), myelodysplastic syndrome (MDS), sponsored by S*BIO. Started Aug 2008; status: completed.
02
Drugs
pacritinib
03
Conditions
myelofibrosis (MF)acute myeloid leukemia (AML)chronic myeloid leukemia (CML)chronic myelomonocytic leukemia (CMML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT00719836.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00719836.